WOODBRIDGE, ON, May 2, 2013 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies
for cardiovascular disease (CVD) and overall health, is pleased to
announce that Dr. George Jackowski, Founder, Chairman and Chief
Scientific Officer was awarded the Queen Elizabeth II Diamond Jubilee
Medal for his significant contribution to the Canadian Biotech and
Pharmaceutical Industries. Prime Minister Stephen Harper presented the
award to Dr. Jackowski on April 30, 2013 in the Prime Minster's
Parliament Hill Office.

"Pivotal congratulates Dr. Jackowski on his Diamond Jubilee Medal,"
stated Mr. Eugene Bortoluzzi, Chief Executive Officer. "As one of the
pioneers of Canadian Biotech over the past thirty years, his
contribution has led to a significant improvement in the quality of
life and care for cardiac patients. Dr. Jackowski is responsible for
saving thousands of lives with the development of the rapid format
cardiac blood test, which remains the standard of care for triaging
patients presenting to the emergency room with chest pain."

Dr. Jackowski developed the first rapid format cardiac test over twenty
years ago, which is currently used worldwide in hospitals and emergency
rooms. The Cardiac Panel point of care test, commonly known as the
"cardiac enzymes", is used to diagnose individuals presenting with
chest pain to the emergency room. Dr. Jackowski's current research
focus on the treatment and prevention of cardiac risk factors, resulted
in the development of Pivotal's unique Omega-3 formulation, VASCAZEN®, for the treatment of an Omega-3 dietary deficiency in cardiovascular
patients.

The Queen Elizabeth Diamond Jubilee Medal honours significant
contributions and achievements by Canadians. The commemorative medal
was created by the Government of Canada to mark the 2012 celebrations
of the 60th anniversary of Her Majesty Queen Elizabeth II's accession to the
Throne.

About Dr. George Jackowski

Dr. Jackowski has founded 12 biotechnology companies in his career.
Additionally, he has contributed to the creation of another 12
biotechnology companies, and the creation of over 1,000 high tech jobs
in the biotech sector. Dr. Jackowski is currently the Chairman and
Chief Scientific Officer of Pivotal Therapeutics Inc. Dr. Jackowski
holds academic positions at the University of Toronto in the Department
of Laboratory Medicine and Pathobiology and the Department of Surgery
and the Florida Atlantic University, the Centre for Molecular Biology
and Biotechnology. Prior to Pivotal, he was Founder, Chairman, CEO and
CSO at SynX Pharma Inc. He has served as the Chairman of Bio Canada
Connect, a Board Member of the Ontario BIOCouncil and on the Board of
Directors for the Canadian Stroke Network. His scientific resume
includes authoring 44 publications and 61 abstracts, holding over 153
patents filed and issued. Dr. Jackowski received the 1996 MEDEC Award
for Medical Achievement for his invention of the Cardiac STATus™
CK-MB/Myoglobin/Troponin Card Test. He developed and holds the patents
on the rapid format immunoassays measuring cardiac enzymes, in
particularly Troponin, which aids in the early diagnosis of myocardial
infarction and is commercialized worldwide in hospital emergency rooms.
Dr. Jackowski has also served on many federal and provincial
governmental biotechnology committees and is on the Scientific Board of
Advisors for the Innovation Cluster, Trent University. Dr. Jackowski
has been intimately involved in the enforcement of patent claims,
patent litigation and patent interference proceedings. Dr. Jackowski,
a respected cardiovascular biochemist, trained at the Cardiovascular
Research Institute at the University of San Francisco, California and
at the Department of Clinical Biochemistry at the University of
Toronto. Dr. Jackowski has over 30 years experience and extensive
networks in the CVD and central nervous system (CNS) disease markets,
particularly pertaining to the commercialization of diagnostic
products.

About VASCAZEN®

VASCAZEN® is a prescription only Medical Food specifically formulated for the
dietary management of an Omega-3 deficiency in cardiovascular patients.
VASCAZEN® is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid
formulation, protected by a series of both U.S. and foreign patents. VASCAZEN® is the second to market prescription only Omega-3 therapy available in
the U.S. and is available by prescription nationwide.

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (OTCQX: PVTTF) (CNSX: PVO)
specialty pharmaceutical company with a focus on cardiovascular disease
and overall health. Pivotal Therapeutics' lead product VASCAZEN® is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications. OMAZENTM is a prescription grade Omega-3 providing >90% total Omega-3 in each
capsule with a unique 6:1 ratio of EPA:DHA. OMAZENTM is a patented product available for sale and distribution in Canada.

Disclosure NoticeThe information contained in this document is as of May 2, 2013. This
press release contains forward-looking statements. Such forward-looking
statements are subject to a number of risks, assumptions and
uncertainties that could cause Pivotal's actual results to differ
materially from those projected in such forward-looking statements.
These statements can be identified by the use of words such as "will",
"anticipate", "estimate", "expect", "project", "forecast", "intend",
"plan", "believe", "project", "potential", and similar expressions with
any discussion of future operating or financial performance or events.
In particular, factors that could cause actual results to differ
materially from those in forward looking statements include the
following: Pivotal's inability to obtain additional financing on
acceptable terms; growth in costs and expenses; inability to compete
with others who provide comparable products; risk that the Company's
products will not gain widespread market acceptance; risks relating to
the Company's ability to maintain its CSNX listing. Forward-looking
statements speak only as of the date made and are not guarantees of
future performance. The Company undertakes no obligation to publicly
update or revise any forward-looking statements contained in this
document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.